Close Menu

circulating tumor DNA

The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.

The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.

The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work. 

The firm said its revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.

The group is validating a next-generating sequencing assay that detects EGFR mutations in ultrashort circulating tumor DNA in matched plasma and saliva samples.

The researchers will compare saliva and plasma samples from 50 patients with non-small cell lung cancer to identify circulating tumor DNA in saliva.

The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.

The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.